belinostat

Also known as PXD-101, PXD101

Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.

Key facts

Drug.N: 2
Drug.H: 14
Drug.IUPAC_name: (2E)-N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
Drug.image: Belinostat.svg
Drug.image_class: skin-invert-image
Drug.tradename: Beleodaq
Drug.pregnancy_US: D
Drug.legal_US: Rx-only
Drug.routes_of_administration: Intravenous (IV)
Drug.bioavailability: 100% (IV)
Drug.protein_bound: 92.9–95.8%
Drug.metabolism: UGT1A1
Drug.excretion

~1 min read

Article

1 sections

Contents

References

Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.

It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.